. 2019 Apr 18;20(8):1913. doi: 10.3390/ijms20081913

Table 5.

Association between changes in the metaplasia score and CDX1 and CDX2 expression (N = 63).

Metaplasia Change	CDX1 Expression Rates, Mean ± SD		p Value
Metaplasia Change	Initial assessment	Final assessment	p Value
Improvement
Antrum (N = 25)	0.217 ± 0.231	0.033 ± 0.091	<0.001
Corpus (N = 11)	0.092 ± 0.103	0.008 ± 0.022	0.019
Exacerbation
Antrum (N = 21)	0.059 ± 0.132	0.100 ± 0.169	0.128
Corpus (N = 6)	0.002 ± 0.005	0.093 ± 0.105	0.080
Metaplasia Change	CDX2 Expression Rate, Mean ± SD		p Value
Metaplasia Change	Initial Assessment	Final Assessment	p Value
Improvement
Antrum (N = 25)	0.195 ± 0.194	0.031 ± 0.059	<0.001
Corpus (N = 11)	0.128 ± 0.168	0.069 ± 0.211	0.401
Exacerbation
Antrum (N = 21)	0.060 ± 0.100	0.114 ± 0.156	0.079
Corpus (N = 6)	0.003 ± 0.007	0.103 ± 0.155	0.159

Improvement and exacerbation were defined as a decrease and increase, respectively, in the updated Sydney system score between the first and final biopsies. Abbreviations: SD, standard deviation; CDX, Caudal related homeobox gene. Bold, statistical significance.